Literature DB >> 21173247

Essential role for mast cell tryptase in acute experimental colitis.

Matthew J Hamilton1, Mark J Sinnamon, Gregory D Lyng, Jonathan N Glickman, Xueli Wang, Wei Xing, Steven A Krilis, Richard S Blumberg, Roberto Adachi, David M Lee, Richard L Stevens.   

Abstract

Patients with inflammatory bowel disease (IBD) have increased numbers of human tryptase-β (hTryptase-β)-positive mast cells (MCs) in the gastrointestinal tract. The amino acid sequence of mouse mast cell protease (mMCP)-6 is most similar to that of hTryptase-β. We therefore hypothesized that this mMCP, or the related tryptase mMCP-7, might have a prominent proinflammatory role in experimental colitis. The dextran sodium sulfate (DSS) and trinitrobenzene sulfonic acid (TNBS) colitis models were used to evaluate the differences between C57BL/6 (B6) mouse lines that differ in their expression of mMCP-6 and mMCP-7 with regard to weight loss, colon histopathology, and endoscopy scores. Microarray analyses were performed, and confirmatory real-time PCR, ELISA, and/or immunohistochemical analyses were carried out on a number of differentially expressed cytokines, chemokines, and matrix metalloproteinases (MMPs). The mMCP-6-null mice that had been exposed to DSS had significantly less weight loss as well as significantly lower pathology and endoscopy scores than similarly treated mMCP-6-expressing mice. This difference in colitis severity was confirmed endoscopically in the TNBS-treated mice. Evaluation of the distal colon segments revealed that numerous proinflammatory cytokines, chemokines that preferentially attract neutrophils, and MMPs that participate in the remodeling of the ECM were all markedly increased in the colons of DSS-treated WT mice relative to untreated WT mice and DSS-treated mMCP-6-null mice. Collectively, our data show that mMCP-6 (but not mMCP-7) is an essential MC-restricted mediator in chemically induced colitis and that this tryptase acts upstream of many of the factors implicated in IBD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21173247      PMCID: PMC3017166          DOI: 10.1073/pnas.1005758108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate.

Authors:  A Venkatraman; B S Ramakrishna; A B Pulimood; S Patra; S Murthy
Journal:  Scand J Gastroenterol       Date:  2000-10       Impact factor: 2.423

2.  Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease.

Authors:  M Raithel; S Winterkamp; A Pacurar; P Ulrich; J Hochberger; E G Hahn
Journal:  Scand J Gastroenterol       Date:  2001-02       Impact factor: 2.423

Review 3.  TNBS-colitis.

Authors:  M Neurath; I Fuss; W Strober
Journal:  Int Rev Immunol       Date:  2000       Impact factor: 5.311

Review 4.  Inflammatory bowel disease.

Authors:  Arthur Kaser; Sebastian Zeissig; Richard S Blumberg
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

5.  Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung.

Authors:  C Huang; G T De Sanctis; P J O'Brien; J P Mizgerd; D S Friend; J M Drazen; L F Brass; R L Stevens
Journal:  J Biol Chem       Date:  2001-05-02       Impact factor: 5.157

6.  Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study.

Authors:  W J Tremaine; A Brzezinski; J A Katz; D C Wolf; T J Fleming; J Mordenti; L C Strenkoski-Nix; M C Kurth
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

7.  Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes.

Authors:  Kichul Shin; Peter A Nigrovic; James Crish; Eric Boilard; H Patrick McNeil; Katherine S Larabee; Roberto Adachi; Michael F Gurish; Reuben Gobezie; Richard L Stevens; David M Lee
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

8.  Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis.

Authors:  Philip Alex; Nicholas C Zachos; Thuan Nguyen; Liberty Gonzales; Tian-E Chen; Laurie S Conklin; Michael Centola; Xuhang Li
Journal:  Inflamm Bowel Dis       Date:  2009-03       Impact factor: 5.325

9.  A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population.

Authors:  Kouichi Asano; Tomonaga Matsushita; Junji Umeno; Naoya Hosono; Atsushi Takahashi; Takahisa Kawaguchi; Takayuki Matsumoto; Toshiyuki Matsui; Yoichi Kakuta; Yoshitaka Kinouchi; Tooru Shimosegawa; Masayo Hosokawa; Yoshiaki Arimura; Yasuhisa Shinomura; Yutaka Kiyohara; Tatsuhiko Tsunoda; Naoyuki Kamatani; Mitsuo Iida; Yusuke Nakamura; Michiaki Kubo
Journal:  Nat Genet       Date:  2009-11-15       Impact factor: 38.330

10.  Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease.

Authors:  Yoshiyuki Nishida; Kunihiko Murase; Hajime Isomoto; Hisashi Furusu; Yohei Mizuta; Robert H Riddell; Shigeru Kohno
Journal:  Hepatogastroenterology       Date:  2002 May-Jun
View more
  51 in total

Review 1.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

2.  Globule Leukocytes and Other Mast Cells in the Mouse Intestine.

Authors:  Peter Vogel; Laura Janke; David M Gravano; Meifen Lu; Deepali V Sawant; Dorothy Bush; E Shuyu; Dario A A Vignali; Asha Pillai; Jerold E Rehg
Journal:  Vet Pathol       Date:  2017-05-11       Impact factor: 2.221

Review 3.  Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing.

Authors:  Jeffrey Douaiher; Julien Succar; Luca Lancerotto; Michael F Gurish; Dennis P Orgill; Matthew J Hamilton; Steven A Krilis; Richard L Stevens
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 4.  Mast cell secretory granules: armed for battle.

Authors:  Sara Wernersson; Gunnar Pejler
Journal:  Nat Rev Immunol       Date:  2014-06-06       Impact factor: 53.106

5.  A Novel, Nonpeptidic, Orally Active Bivalent Inhibitor of Human β-Tryptase.

Authors:  Sarah F Giardina; Douglas S Werner; Maneesh Pingle; Donald E Bergstrom; Lee D Arnold; Francis Barany
Journal:  Pharmacology       Date:  2018-08-22       Impact factor: 2.547

6.  Munc13 proteins control regulated exocytosis in mast cells.

Authors:  Elsa M Rodarte; Marco A Ramos; Alfredo J Davalos; Daniel C Moreira; David S Moreno; Eduardo I Cardenas; Alejandro I Rodarte; Youlia Petrova; Sofia Molina; Luis E Rendon; Elizabeth Sanchez; Keegan Breaux; Alejandro Tortoriello; John Manllo; Erika A Gonzalez; Michael J Tuvim; Burton F Dickey; Alan R Burns; Ruth Heidelberger; Roberto Adachi
Journal:  J Biol Chem       Date:  2017-11-15       Impact factor: 5.157

Review 7.  The multifaceted mast cell in inflammatory bowel disease.

Authors:  Matthew J Hamilton; Sandra M Frei; Richard L Stevens
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

8.  A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis.

Authors:  Emma L Beckett; Richard L Stevens; Andrew G Jarnicki; Richard Y Kim; Irwan Hanish; Nicole G Hansbro; Andrew Deane; Simon Keely; Jay C Horvat; Ming Yang; Brian G Oliver; Nico van Rooijen; Mark D Inman; Roberto Adachi; Roy J Soberman; Sahar Hamadi; Peter A Wark; Paul S Foster; Philip M Hansbro
Journal:  J Allergy Clin Immunol       Date:  2013-02-04       Impact factor: 10.793

9.  Early life stress triggers persistent colonic barrier dysfunction and exacerbates colitis in adult IL-10-/- mice.

Authors:  E M Lennon; Nitsan Maharshak; H Elloumi; L Borst; S E Plevy; Adam J Moeser
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

10.  Flexible colonoscopy in mice to evaluate the severity of colitis and colorectal tumors using a validated endoscopic scoring system.

Authors:  Tomohiro Kodani; Alex Rodriguez-Palacios; Daniele Corridoni; Loris Lopetuso; Luca Di Martino; Brian Marks; James Pizarro; Theresa Pizarro; Amitabh Chak; Fabio Cominelli
Journal:  J Vis Exp       Date:  2013-10-16       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.